Efficacy and Safety of 8-Weeks of Glecaprevir/Pibrentasvir in Treatment-Naive Adults with HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

被引：0
|
作者：
Fontana, Robert J. [1 ]
Lens, Sabela [2 ,3 ]
McPherson, Stuart [4 ,5 ]
Elkhashab, Magdy [6 ]
Katzarov, Krum [7 ]
Pires, Ana Gabriela [8 ]
Xue, Zhenyi [8 ]
Trinh, Roger [8 ]
Rodrigues, Lino, Jr. [8 ]
Porcalla, Ariel [8 ]
Zeuzem, Stefan [9 ]
机构：
[1] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA
[2] Idibaps, Hosp Clin, Liver Unit, Barcelona, Spain
[3] Ciberehd, Madrid, Spain
[4] Newcastle Upon Tyne Hosp NHS Fdn & Trust, Liver Unit, Newcastle Upon Tyne, Tyne & Wear, England
[5] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England
[6] Toronto Liver Ctr, Toronto, ON, Canada
[7] Mil Med Acad, Dept Gastroenterol Hepatopancreatobiliary HPB Sur, Belgrade, Serbia
[8] Abbvie Inc, N Chicago, IL USA
[9] Goethe Univ Frankfurt, Frankfurt, Germany
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
653
引用
收藏
页码：388A / 389A
页数：2
相关论文
共 50 条
  • [21] Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection
    Bernstein, David E.
    Foster, Graham
    Dylla, Douglas
    Mauss, Stefan
    Nelson, David
    Asselah, Tarik
    Flamm, Steven
    Cooper, Curtis
    Liu, Ran
    Viani, Rolando
    Wang, Stanley
    Mensa, Federico
    Sulkowski, Mark
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S490 - S490
  • [22] MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection
    Reau, N.
    Kwo, P. Y.
    Rhee, S.
    Brown, R. S., Jr.
    Agarwal, K.
    Angus, P.
    Gane, E.
    Kao, J. -H.
    Mantry, P. S.
    Reddy, K. R.
    Tran, T. T.
    Hu, Y. B.
    Gulati, A.
    Ng, T. I.
    Dumas, E. O.
    Shulman, N.
    Trinh, R.
    Forns, X.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S90 - S91
  • [23] Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
    Gane, Edward J.
    Poordad, Fred
    Zadeikis, Neddie
    Valdes, Joaquin M.
    Lin, Chih-Wei
    Liu, Wei
    Asatryan, Armen
    Wang, Stanley
    Stedman, Catherine A.
    Greenbloom, Susan
    Nguyen, Tuan T.
    Elkhashab, Magdy
    Harlan, William R.
    Woerns, Marcus A.
    Tran, Albert
    Mulkay, Jean-Pierre
    Yu, Yao
    Pilot-Matias, Tami
    Porcalla, Ariel R.
    Mensa, Federico J.
    HEPATOLOGY, 2017, 66 : 44A - 44A
  • [24] Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1-6 and chronic kidney disease: an integrated analysis
    Pol, S.
    Pockros, P.
    Pugatch, D.
    Brau, N.
    Landis, C.
    Elkhashab, M.
    Sasadeusz, J.
    Tran, A.
    Hu, Y.
    Kosloski, M.
    Mensa, F.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S738 - S738
  • [25] Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Patients with Genotypes 1-6 Chronic HCV Infection: Part 1 of the Dora Study
    Jonas, Maureen M.
    Squires, Robert H.
    Rhee, Susan M.
    Lin, Chih-Wei
    Bessho, Kazuhiko
    Feiterna-Sperling, Cornelia
    Hierro, Loreto
    Kelly, Deirdre A.
    Ling, Simon C.
    Strokova, Tatiana
    Del Valle-Segarre, Antonio
    Liu, Li
    Ng, Teresa
    Porcalla, Ariel
    Burroughs, Margaret
    Sokal, Etienne M.
    HEPATOLOGY, 2018, 68 : 1347A - 1348A
  • [26] Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
    Robert J. Fontana
    Sabela Lens
    Stuart McPherson
    Magdy Elkhashab
    Victor Ankoma-Sey
    Mark Bondin
    Ana Gabriela Pires dos Santos
    Zhenyi Xue
    Roger Trinh
    Ariel Porcalla
    Stefan Zeuzem
    Advances in Therapy, 2019, 36 : 3458 - 3470
  • [27] Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease
    Gane, Edward
    Poordad, Fred
    Zadeikis, Neddie
    Valdes, Joaquin
    Lin, Chih-Wei
    Liu, Wei
    Asatryan, Armen
    Wang, Stanley
    Stedman, Catherine
    Greenbloom, Susan
    Tuan Nguyen
    Elkhashab, Magdy
    Worns, Marcus-Alexander
    Tran, Albert
    Mulkay, Jean-Pierre
    Setze, Carolyn
    Yu, Yao
    Pilot-Matias, Tami
    Porcalla, Ariel
    Mensa, Federico J.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (10) : 1657 - 1664
  • [28] Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infection
    Persico, M.
    Flisiak, R.
    Abunimeh, M.
    Sise, M.
    Park, J. Y.
    Kaskas, M.
    Bruchfeld, A.
    Woerns, M. -A.
    Aglitti, A.
    Xue, Z.
    Rullman, J.
    Pocalla, A.
    Lawitz, E.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S292 - S292
  • [29] ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis
    Foster, G. R.
    Gane, E.
    Asatryan, A.
    Asselah, T.
    Ruane, P. J.
    Pol, S.
    Poordad, F.
    Stedman, C. A.
    Dore, G.
    Roberts, S. K.
    Kaita, K.
    Vierling, J.
    Vargas, H. E.
    Kort, J.
    Lin, C. -W.
    Liu, R.
    Ng, T.
    Mensa, F.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S33 - S33
  • [30] HIGH SVR RATES WITH EIGHT AND TWELVE WEEKS OF PANGENOTYPIC GLECAPREVIR/PIBRENTASVIR: INTEGRATED EFFICACY ANALYSIS OF GENOTYPE 1-6 PATIENTS WITHOUT CIRRHOSIS
    Puoti, Massimo
    Foster, Graham R.
    Wang, Stanley
    Mutimer, David J.
    Gane, Edward
    Moreno, Christophe
    Chang, Ting Tsung
    Lee, Sam
    Marinho, Rui T.
    DuFour, Jean-Francois
    Pol, Stanislas
    Hezode, Christophe
    Gordon, Stuart C.
    Strasser, Simone I.
    Thuluvath, Paul J.
    Liu, Ran
    Pilot-Matias, Tami
    Mensa, Federico
    GASTROENTEROLOGY, 2017, 152 (05) : S1059 - S1059
12345